Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SCD | O00767 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418952 | 0.88 | KDM4E (0.50) | KDM4ESMN1; SMN2TP53SCD5MAPT | |
| SCHEMBL15190572 | 0.87 | SCD5 (0.61) | KDM4ESMN1; SMN2SCD5MAPTHPGD | |
| SCHEMBL2734042 | 0.86 | PTGER1 (0.64) | KDM4ESCD5PTGER1SCDALDH1A1 | |
| SCHEMBL4423566 | 0.86 | SCD5 (0.55) | KDM4ESMN1; SMN2TP53SCD5MAPT | |
| SCHEMBL2724122 | 0.85 | MAPT (0.64) | KDM4ESMN1; SMN2TP53SCD5MAPT | |
| SCHEMBL2732886 | 0.82 | PTGER1 (0.59) | KDM4ESMN1; SMN2SCD5PTGER1SCD | |
| SCHEMBL758016 | 0.82 | PTGER1 (0.57) | SMN1; SMN2MAPTNPSR1HPGDPTGER1 | |
| SCHEMBL4427183 | 0.81 | MAPT (0.62) | KDM4ESMN1; SMN2TP53SCD5MAPT | |
| SCHEMBL2731497 | 0.81 | PTGER1 (0.55) | KDM4ESMN1; SMN2SCD5MAPTMEN1 | |
| SCHEMBL4420388 | 0.79 | MAPT (0.59) | KDM4ESMN1; SMN2TP53SCD5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | claimed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | claimed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| WO-2012052459-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | NLRP3, IL33, IL5 | KDM4E 2143/4885SMN1; SMN2 4836/4885TP53 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.